| Also known as |
Tenelia, Teneglucon |
| Blood pressure |
Can slightly reduce blood pressure |
| Chemical name |
(2S)-2-[[4-[(3-methyl-1-phenyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl]amino]butanoic acid |
| Dosage (medical) |
Typically 20 mg once daily |
| Dosage (sports) |
Not applicable as not used for enhancing athletic performance |
| Effects |
Improves blood sugar control in type 2 diabetes |
| Formula |
C22H30N6O2 |
| Half-life |
24 hours approximately |
| Hepatotoxicity |
Low risk |
| Lab Test |
Monitoring blood glucose levels |
| Main action |
Antidiabetic, increases insulin release and decreases glucagon levels |
| Side effects |
Hypoglycemia, headache, nasopharyngitis, upper respiratory tract infection |
| Storage conditions |
Store at room temperature, away from moisture and heat |
| Strength |
20 mg |
| Substance class |
Dipeptidyl peptidase-4 (DPP-4) inhibitor |
| Trade name |
Tenelia |
| Use in sports |
None, not a performance-enhancing drug |
| Water Retention |
No significant water retention |
| Manufacturer |
Glenmark Pharmaceuticals Ltd. |
